AbbVie

News

Bottle of Qulipta superimposed on image of woman holding head against sun dappled wall

AbbVie charts a new course for CGRPs in menstrual migraine

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

News

AbbVie's cancer TCE etentamig hits the mark in myeloma

AbbVie has reported positive results with CD3xBCMA bispecific etentamig in multiple myeloma, but can it break into a crowded market?

News

Another 340B lawsuit gets underway, in Illinois

Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.

News

EU first to clear AbbVie's Rinvoq for alopecia areata

AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.

News

Drugmakers asked to defend Chinese trials; reports

The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.

News

AbbVie climbs post-Allergan M&A peak with Apogee buy

AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.

AbbVie charts a new course for CGRPs in menstrual migraine

AbbVie's cancer TCE etentamig hits the mark in myeloma

Another 340B lawsuit gets underway, in Illinois

EU first to clear AbbVie's Rinvoq for alopecia areata

Drugmakers asked to defend Chinese trials; reports

AbbVie climbs post-Allergan M&A peak with Apogee buy

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks